ALURD (Allurion Technologies) Moat Score: 3/10 (As of Jun. 24, 2026)


ALURD Allurion Technologies Inc ALURD
16 GF Score
Price $5.91
GF Value $10.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Allurion Technologies Moat Score?

Allurion Technologies ALURD -2.11% 16 Moat Score is 3 as of Jun. 24, 2026. GuruFocus rates ALURD with a GF Score™ of 16/100 and a GF Value™ of $10.66 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Allurion Technologies ranks better than 75.77% on this metric.

Allurion Technologies has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Allurion Technologies has No Moat: Allurion Technologies Inc lacks significant market leadership or customer switching costs. The company does not possess strong brand strength or durable cost advantages. Its intellectual property and innovation capabilities are not sufficient to establish a competitive edge, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Allurion Technologies might have No Moat - Very weak/transient advantages.


Allurion Technologies  (OTCPK:ALURD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Allurion Technologies Moat Score Related Terms


ALURD vs ALRTF, VVOS, SINT: Moat Score Comparison

For the Medical Devices subindustry, Allurion Technologies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Moat Score distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Moat Score falls into.


ALURD
16GF Score
Allurion Technologies Inc ALURD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Allurion Technologies (ALURD) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Allurion Technologies ranks #205 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 24.2%.
Is Allurion Technologies' Moat Score too high?
Allurion Technologies' current Moat Score is 3. Based on the distribution chart, Allurion Technologies ranks #205 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Allurion Technologies has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' Moat Score compare to ALRTF and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #205 out of 846 companies for Moat Score. This places Allurion Technologies in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Allurion Technologies's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.66, compared to a current price of $5.91 — trading 44.6% below its estimated fair value. The current Moat Score is 3. Allurion Technologies' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allurion Technologies (ALURD) Overvalued in 2026?

Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued. The current stock price of $5.91 is trading 44.6% below its estimated GF Value™ of $10.66. GuruFocus considers Allurion Technologies to be Possible Value Trap.

Key valuation signals for ALURD:

  • Moat Score: 3
  • GF Value™: $10.66 vs. price of $5.91 (44.6% below fair value)
  • GF Score™: 16/100 with 4 warning signs

No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Allurion Technologies Business Description

Address 11 Huron Drive, Natick, MA, USA, 01760
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
16GF Score

Get the complete analysis for ALURD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.91
Price
$10.66
GF Value